A quarter of people with HCV initially refused access to sofosbuvir/lepidasvir

A quarter of people with HCV initially refused access to sofosbuvir/lepidasvir … Treatment of HCV infection has been revolutionised by the development of direct-acting antiviral (DDA) agents. Compared to traditional therapy with pegylated interferon/ribavirin, treatment with DDAs is associated with … Continue reading